These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38846086)

  • 21. Renal cyst evolution in childhood: a contemporary observational study.
    Rediger C; Guerra LA; Keays MA; Wayne C; Reddy D; Ksara S; Leonard MP
    J Pediatr Urol; 2019 Apr; 15(2):188.e1-188.e6. PubMed ID: 30808538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
    Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
    Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.
    Saini AK; Saini R; Singh S
    Mol Med; 2020 Dec; 26(1):128. PubMed ID: 33308138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research progress in autosomal dominant polycystic kidney disease].
    Hu S; Li D; Tan X; Gu J; Chen M; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan.
    Müller RU; Haas CS; Sayer JA
    Clin Kidney J; 2018 Feb; 11(1):62-69. PubMed ID: 29423204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Zhou JX; Torres VE
    Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD
    Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.
    Magistroni R; Boletta A
    J Nephrol; 2017 Aug; 30(4):511-519. PubMed ID: 28390001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolomic profiling to identify early urinary biomarkers and metabolic pathway alterations in autosomal dominant polycystic kidney disease.
    Houske EA; Glimm MG; Bergstrom AR; Slipher SK; Welhaven HD; Greenwood MC; Linse GM; June RK; Yu ASL; Wallace DP; Hahn AK
    Am J Physiol Renal Physiol; 2023 Jun; 324(6):F590-F602. PubMed ID: 37141147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?
    Ponticelli C; Moroni G; Reggiani F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
    Hines CB; Hooper GL; Collins-Yoder A
    Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycystic Kidney/Liver Disease.
    Roediger R; Dieterich D; Chanumolu P; Deshpande P
    Clin Liver Dis; 2022 May; 26(2):229-243. PubMed ID: 35487607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.